T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, David Lieberman et al.|Nature Medicine|2024Cited by 254
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer modelsPatrizia Porazzi, Marco Ruella, Siena Nason et al.|Cancer Cell|2025Cited by 47
CD5 deletion enhances the antitumor activity of adoptive T cell therapiesRuchi P. Patel, Patrizia Porazzi, Guido Ghilardi et al.|Science Immunology|2024Cited by 45
The BTLA–HVEM axis restricts CAR T cell efficacy in cancerPuneeth Guruprasad, Marco Ruella, Alberto Carturan et al.|Nature Immunology|2024Cited by 41
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human studyYunlin Zhang, Marco Ruella, Ruchi P. Patel et al.|Molecular Cancer|2023Cited by 32